Aerovate Therapeutics (AVTE) Competitors

$24.52 +0.29 (+1.20%)

As of 05/4/2026

AVTE vs. BEAM, GMTX, DYN, ARQT, and MOR

Should you be buying Aerovate Therapeutics stock or one of its competitors? The main competitors of Aerovate Therapeutics include Beam Therapeutics (BEAM), Gemini Therapeutics (GMTX), Dyne Therapeutics (DYN), Arcutis Biotherapeutics (ARQT), and MorphoSys (MOR). These companies are all part of the "pharmaceutical products" industry.

How does Aerovate Therapeutics compare to Beam Therapeutics?

Aerovate Therapeutics (NASDAQ:AVTE) and Beam Therapeutics (NASDAQ:BEAM) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, risk, profitability, institutional ownership, media sentiment, earnings and dividends.

: Beam Therapeutics has a consensus price target of $49.36, suggesting a potential upside of 70.79%. Given Beam Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Beam Therapeutics is more favorable than Aerovate Therapeutics.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Aerovate Therapeutics
0 Sell rating(s)
0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
0.00
Beam Therapeutics
1 Sell rating(s)

3 Hold rating(s)

11 Buy rating(s)

1 Strong Buy rating(s)
2.75
: Aerovate Therapeutics has a beta of 0.95, indicating that its share price is 5% less volatile than the S&P 500. Comparatively, Beam Therapeutics has a beta of 2.26, indicating that its share price is 126% more volatile than the S&P 500.
: In the previous week, Beam Therapeutics had 5 more articles in the media than Aerovate Therapeutics. MarketBeat recorded 6 mentions for Beam Therapeutics and 1 mentions for Aerovate Therapeutics. Aerovate Therapeutics' average media sentiment score of 0.75 beat Beam Therapeutics' score of 0.65 indicating that Aerovate Therapeutics is being referred to more favorably in the media.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Aerovate Therapeutics
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Beam Therapeutics
1 Very Positive mention(s)
3 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
: 99.7% of Beam Therapeutics shares are owned by institutional investors. 24.9% of Aerovate Therapeutics shares are owned by insiders. Comparatively, 3.8% of Beam Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
: Aerovate Therapeutics has a net margin of 0.00% compared to Beam Therapeutics' net margin of -57.24%. Beam Therapeutics' return on equity of -30.65% beat Aerovate Therapeutics' return on equity.
Company Net Margins Return on Equity Return on Assets
Aerovate Therapeutics N/A -90.19% -77.47%
Beam Therapeutics -57.24% -30.65% -23.73%
: Aerovate Therapeutics has higher earnings, but lower revenue than Beam Therapeutics. Beam Therapeutics is trading at a lower price-to-earnings ratio than Aerovate Therapeutics, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Aerovate Therapeutics N/A N/A -$75.52M -$1.70 N/A
Beam Therapeutics $139.74M 21.25 -$79.99M -$1.01 N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aerovate Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Beam Therapeutics	1 Sell rating(s)	3 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.75

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aerovate Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Beam Therapeutics	1 Very Positive mention(s)	3 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Company	Net Margins	Return on Equity	Return on Assets
Aerovate Therapeutics	N/A	-90.19%	-77.47%
Beam Therapeutics	-57.24%	-30.65%	-23.73%

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aerovate Therapeutics	N/A	N/A	-$75.52M	-$1.70	N/A
Beam Therapeutics	$139.74M	21.25	-$79.99M	-$1.01	N/A

Summary

Beam Therapeutics beats Aerovate Therapeutics on 11 of the 16 factors compared between the two stocks.

How does Aerovate Therapeutics compare to Gemini Therapeutics?

Gemini Therapeutics (NASDAQ:GMTX) and Aerovate Therapeutics (NASDAQ:AVTE) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, dividends, risk, profitability, media sentiment, analyst recommendations and institutional ownership.

: Gemini Therapeutics' return on equity of -38.78% beat Aerovate Therapeutics' return on equity.
Company Net Margins Return on Equity Return on Assets
Gemini Therapeutics N/A -38.78% -35.88%
Aerovate Therapeutics N/A -90.19% -77.47%
: 75.4% of Gemini Therapeutics shares are owned by institutional investors. 12.9% of Gemini Therapeutics shares are owned by company insiders. Comparatively, 24.9% of Aerovate Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
: Gemini Therapeutics is trading at a lower price-to-earnings ratio than Aerovate Therapeutics, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Gemini Therapeutics N/A N/A -$71.87M -$1.00 N/A
Aerovate Therapeutics N/A N/A -$75.52M -$1.70 N/A
: In the previous week, Gemini Therapeutics and Gemini Therapeutics both had 1 articles in the media. Aerovate Therapeutics' average media sentiment score of 0.75 beat Gemini Therapeutics' score of 0.00 indicating that Aerovate Therapeutics is being referred to more favorably in the news media.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Gemini Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Aerovate Therapeutics
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
: Gemini Therapeutics has a beta of -0.12, indicating that its share price is 112% less volatile than the S&P 500. Comparatively, Aerovate Therapeutics has a beta of 0.95, indicating that its share price is 5% less volatile than the S&P 500.

Company	Net Margins	Return on Equity	Return on Assets
Gemini Therapeutics	N/A	-38.78%	-35.88%
Aerovate Therapeutics	N/A	-90.19%	-77.47%

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Gemini Therapeutics	N/A	N/A	-$71.87M	-$1.00	N/A
Aerovate Therapeutics	N/A	N/A	-$75.52M	-$1.70	N/A

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Gemini Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Aerovate Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Gemini Therapeutics beats Aerovate Therapeutics on 5 of the 9 factors compared between the two stocks.

How does Aerovate Therapeutics compare to Dyne Therapeutics?

Dyne Therapeutics (NASDAQ:DYN) and Aerovate Therapeutics (NASDAQ:AVTE) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, profitability, earnings, dividends, valuation, media sentiment, analyst recommendations and institutional ownership.

: Dyne Therapeutics' return on equity of -61.46% beat Aerovate Therapeutics' return on equity.
Company Net Margins Return on Equity Return on Assets
Dyne Therapeutics N/A -61.46% -50.94%
Aerovate Therapeutics N/A -90.19% -77.47%
: Aerovate Therapeutics is trading at a lower price-to-earnings ratio than Dyne Therapeutics, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Dyne Therapeutics N/A N/A -$446.21M -$3.54 N/A
Aerovate Therapeutics N/A N/A -$75.52M -$1.70 N/A
: In the previous week, Dyne Therapeutics had 5 more articles in the media than Aerovate Therapeutics. MarketBeat recorded 6 mentions for Dyne Therapeutics and 1 mentions for Aerovate Therapeutics. Dyne Therapeutics' average media sentiment score of 0.95 beat Aerovate Therapeutics' score of 0.75 indicating that Dyne Therapeutics is being referred to more favorably in the media.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Dyne Therapeutics
3 Very Positive mention(s)
2 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Aerovate Therapeutics
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
: Dyne Therapeutics has a beta of 1.08, indicating that its share price is 8% more volatile than the S&P 500. Comparatively, Aerovate Therapeutics has a beta of 0.95, indicating that its share price is 5% less volatile than the S&P 500.
: Dyne Therapeutics presently has a consensus price target of $35.14, indicating a potential upside of 101.16%. Given Dyne Therapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe Dyne Therapeutics is more favorable than Aerovate Therapeutics.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Dyne Therapeutics
1 Sell rating(s)
2 Hold rating(s)

11 Buy rating(s)

3 Strong Buy rating(s)
2.94
Aerovate Therapeutics
0 Sell rating(s)

0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
0.00
: 96.7% of Dyne Therapeutics shares are owned by institutional investors. 20.8% of Dyne Therapeutics shares are owned by insiders. Comparatively, 24.9% of Aerovate Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Company	Net Margins	Return on Equity	Return on Assets
Dyne Therapeutics	N/A	-61.46%	-50.94%
Aerovate Therapeutics	N/A	-90.19%	-77.47%

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dyne Therapeutics	N/A	N/A	-$446.21M	-$3.54	N/A
Aerovate Therapeutics	N/A	N/A	-$75.52M	-$1.70	N/A

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Dyne Therapeutics	3 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Aerovate Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dyne Therapeutics	1 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	3 Strong Buy rating(s)	2.94
Aerovate Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

Dyne Therapeutics beats Aerovate Therapeutics on 11 of the 14 factors compared between the two stocks.

How does Aerovate Therapeutics compare to Arcutis Biotherapeutics?

Aerovate Therapeutics (NASDAQ:AVTE) and Arcutis Biotherapeutics (NASDAQ:ARQT) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, earnings, valuation, media sentiment, analyst recommendations, risk, institutional ownership and dividends.

: Arcutis Biotherapeutics has a consensus price target of $34.00, suggesting a potential upside of 45.18%. Given Arcutis Biotherapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Arcutis Biotherapeutics is more favorable than Aerovate Therapeutics.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Aerovate Therapeutics
0 Sell rating(s)
0 Hold rating(s)

0 Buy rating(s)

0 Strong Buy rating(s)
0.00
Arcutis Biotherapeutics
1 Sell rating(s)

2 Hold rating(s)

5 Buy rating(s)

0 Strong Buy rating(s)
2.50
: Aerovate Therapeutics has a net margin of 0.00% compared to Arcutis Biotherapeutics' net margin of -4.29%. Arcutis Biotherapeutics' return on equity of -10.26% beat Aerovate Therapeutics' return on equity.
Company Net Margins Return on Equity Return on Assets
Aerovate Therapeutics N/A -90.19% -77.47%
Arcutis Biotherapeutics -4.29% -10.26% -4.30%
: Aerovate Therapeutics has a beta of 0.95, suggesting that its share price is 5% less volatile than the S&P 500. Comparatively, Arcutis Biotherapeutics has a beta of 1.58, suggesting that its share price is 58% more volatile than the S&P 500.
: Arcutis Biotherapeutics has higher revenue and earnings than Aerovate Therapeutics. Arcutis Biotherapeutics is trading at a lower price-to-earnings ratio than Aerovate Therapeutics, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Aerovate Therapeutics N/A N/A -$75.52M -$1.70 N/A
Arcutis Biotherapeutics $376.07M 7.79 -$16.14M -$0.14 N/A
: In the previous week, Arcutis Biotherapeutics had 4 more articles in the media than Aerovate Therapeutics. MarketBeat recorded 5 mentions for Arcutis Biotherapeutics and 1 mentions for Aerovate Therapeutics. Arcutis Biotherapeutics' average media sentiment score of 1.00 beat Aerovate Therapeutics' score of 0.75 indicating that Arcutis Biotherapeutics is being referred to more favorably in the news media.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Aerovate Therapeutics
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Arcutis Biotherapeutics
4 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aerovate Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Arcutis Biotherapeutics	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50

Company	Net Margins	Return on Equity	Return on Assets
Aerovate Therapeutics	N/A	-90.19%	-77.47%
Arcutis Biotherapeutics	-4.29%	-10.26%	-4.30%

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aerovate Therapeutics	N/A	N/A	-$75.52M	-$1.70	N/A
Arcutis Biotherapeutics	$376.07M	7.79	-$16.14M	-$0.14	N/A

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aerovate Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Arcutis Biotherapeutics	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Arcutis Biotherapeutics beats Aerovate Therapeutics on 11 of the 13 factors compared between the two stocks.

How does Aerovate Therapeutics compare to MorphoSys?

Aerovate Therapeutics (NASDAQ:AVTE) and MorphoSys (NASDAQ:MOR) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, earnings, valuation, media sentiment, analyst recommendations, risk, institutional ownership and dividends.

: Aerovate Therapeutics has a net margin of 0.00% compared to MorphoSys' net margin of -226.79%. Aerovate Therapeutics' return on equity of -90.19% beat MorphoSys' return on equity.
Company Net Margins Return on Equity Return on Assets
Aerovate Therapeutics N/A -90.19% -77.47%
MorphoSys -226.79% -694.31% -22.55%
: Aerovate Therapeutics has higher earnings, but lower revenue than MorphoSys. Aerovate Therapeutics is trading at a lower price-to-earnings ratio than MorphoSys, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Aerovate Therapeutics N/A N/A -$75.52M -$1.70 N/A
MorphoSys $238.28M 11.99 -$205.35M -$3.48 N/A
: 18.4% of MorphoSys shares are owned by institutional investors. 24.9% of Aerovate Therapeutics shares are owned by company insiders. Comparatively, 0.1% of MorphoSys shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
: In the previous week, Aerovate Therapeutics had 1 more articles in the media than MorphoSys. MarketBeat recorded 1 mentions for Aerovate Therapeutics and 0 mentions for MorphoSys. Aerovate Therapeutics' average media sentiment score of 0.75 beat MorphoSys' score of 0.00 indicating that Aerovate Therapeutics is being referred to more favorably in the media.
Company Overall Sentiment
Aerovate Therapeutics Positive
MorphoSys Neutral
: Aerovate Therapeutics has a beta of 0.95, suggesting that its share price is 5% less volatile than the S&P 500. Comparatively, MorphoSys has a beta of 1.2, suggesting that its share price is 20% more volatile than the S&P 500.

Company	Net Margins	Return on Equity	Return on Assets
Aerovate Therapeutics	N/A	-90.19%	-77.47%
MorphoSys	-226.79%	-694.31%	-22.55%

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aerovate Therapeutics	N/A	N/A	-$75.52M	-$1.70	N/A
MorphoSys	$238.28M	11.99	-$205.35M	-$3.48	N/A

Company	Overall Sentiment
Aerovate Therapeutics	Positive
MorphoSys	Neutral

Summary

Aerovate Therapeutics beats MorphoSys on 7 of the 12 factors compared between the two stocks.

Get Aerovate Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AVTE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

AVTE vs. The Competition

Export

Metric	Aerovate Therapeutics	Pharmaceutical Industry	Medical Sector	NASDAQ Exchange
Market Cap	$710.71M	$892.30M	$6.25B	$11.87B
Dividend Yield	N/A	4.84%	2.73%	5.21%
P/E Ratio	-8.20	1.72	29.03	28.47
Price / Sales	N/A	120.12	476.10	60.92
Price / Cash	N/A	20.07	27.62	36.52
Price / Book	6.19	7.60	9.67	6.67
Net Income	-$75.52M	-$4.80M	$3.55B	$332.53M
7 Day Performance	-8.68%	0.09%	1.75%	2.03%
1 Month Performance	58.30%	5.64%	5.66%	9.23%
1 Year Performance	96.47%	30.92%	34.42%	39.62%

Aerovate Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
AVTE Aerovate Therapeutics	N/A	$24.52 +1.2%	N/A	N/A	$710.71M	N/A	N/A	20	High Trading Volume
BEAM Beam Therapeutics	2.8854 of 5 stars	$30.56 +4.8%	$49.36 +61.5%	N/A	$3.00B	$139.74M	N/A	510
GMTX Gemini Therapeutics	N/A	$68.85 flat	N/A	N/A	$2.98B	N/A	N/A	30
DYN Dyne Therapeutics	3.4525 of 5 stars	$18.16 +0.7%	$35.14 +93.5%	N/A	$2.98B	N/A	N/A	100	Analyst Downgrade
ARQT Arcutis Biotherapeutics	3.3955 of 5 stars	$23.29 -0.6%	$34.00 +46.0%	N/A	$2.93B	$376.07M	N/A	150	Upcoming Earnings

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:AVTE) was last updated on 5/5/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Aerovate Therapeutics (AVTE) Competitors

AVTE vs. BEAM, GMTX, DYN, ARQT, and MOR

How does Aerovate Therapeutics compare to Beam Therapeutics?

Summary

How does Aerovate Therapeutics compare to Gemini Therapeutics?

Summary

How does Aerovate Therapeutics compare to Dyne Therapeutics?

Summary

How does Aerovate Therapeutics compare to Arcutis Biotherapeutics?

Summary

How does Aerovate Therapeutics compare to MorphoSys?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AVTE vs. The Competition

Aerovate Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Aerovate Therapeutics (AVTE) Competitors

AVTE vs. BEAM, GMTX, DYN, ARQT, and MOR

How does Aerovate Therapeutics compare to Beam Therapeutics?

Summary

How does Aerovate Therapeutics compare to Gemini Therapeutics?

Summary

How does Aerovate Therapeutics compare to Dyne Therapeutics?

Summary

How does Aerovate Therapeutics compare to Arcutis Biotherapeutics?

Summary

How does Aerovate Therapeutics compare to MorphoSys?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AVTE vs. The Competition

Aerovate Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools